The recent decision by UK food regulators to drastically reduce the recommended daily dose of cannabidiol (CBD) may prove to have a significant impact on Greenhouse Hemp Growers in the UK.
The Food Standards Agency (FSA) and its Scottish counterpart have revised their guidance, advising healthy adults to limit their CBD intake from food to 10mg per day, down from the previous 70mg. This decision, influenced by new evidence indicating a risk of liver damage and thyroid issues, has been met with concern by the cannabis industry.
Professor Robin May, the FSA’s chief scientific advisor, warned, “The more CBD you consume over your lifetime, the more likely you are to develop long-term adverse effects, like liver damage or thyroid issues.” This change is expected to send shockwaves through the industry, especially among Greenhouse Hemp Growers who have been capitalising on the booming CBD market.
CBD, a non-psychoactive chemical found in the hemp plant, has been a popular ingredient in a range of products from edibles to cosmetics. The reduction in the recommended dosage could potentially affect the sale and production of these products. Marika Graham-Woods, executive director of the Cannabis Trades Association, criticised the decision, stating, “All this does is frighten consumers and retailers and it stops the industry going forward again. I don’t see any benefit in what they have done.”
For Greenhouse Hemp Growers, particularly those involved in the cultivation of hemp for CBD extraction, this revised guidance could influence cultivation practices, product formulation, and market demand. The FSA’s decision underscores the need for ongoing research and regulation to ensure both consumer safety and industry stability.
In the context of the UK’s greenhouse hemp growers, this development could necessitate adjustments in cultivation and extraction processes to align with the new guidelines. The industry, while adapting to these changes, may also face challenges in maintaining consumer confidence and market stability.